---
schema_version: "secwatch.filing_event.v1"
accession: "0001001233-25-000006"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:11:32.826371+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026

## Summary
- Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.
- All 18 patients on ERT at baseline safely withdrew; one later resumed per physician's decision.
- 69% of patients improved FOS-MSSI severity score at 12 months; SF-36 QoL scores showed statistically significant gains.
- BLA submission for isaralgagene civaparvovec targeted Q1 2026 under Accelerated Approval pathway, subject to funding.
- Company notes need for substantial additional capital to continue as going concern and advance Fabry program.

## SEC filing metadata
- accession: 0001001233-25-000006
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000006/0001001233-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000006/sgmo-20250904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001001233-25-000006
- JSON: https://secwatch.observer/filing/0001001233-25-000006.json
- Plain text: https://secwatch.observer/filing/0001001233-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.